Use of chronic lymphocytic leukemia-international prognostic index in patient risk stratification-single center experience

Sanja Trajkova, Lidija Cevreska, Svetlana Krstevska -Balkanov, Aleksandra Pivkova -Veljanovska, Marija Popova-Labacevska, Aleksandra Jovanovska, Nevenka Ridova, Simona Stojanovska, Irina Panovska-Stavridis


Background: Several prognostic factors have been identified to predict the outcome of patients with chronic lymphocytic leukemia (CLL). To predict the time to first treatment (TFT) we integrated the data of clinical and biological markers in CLL-International prognostic index (CLL-IPI). Aim of the study was the determination of the impact of CLL-IPI in prediction of TFS in CLL patents.

Methods: The study was set up retrospectively and included 90 patients with CLL diagnosed and treated at the university clinic of hematology for a period of time from January 2012 to January 2020. We incorporated the data of Binet staging system, most adverse cytogenetic marker and mutational status of immunoglobulin heavy chain in CLL-IPI.

Results: The statistical data of the 90 patients showed that the median TFS for low CLL-IPI (N=24), intermediate CLL-IPI (N=40), high risk CLL-IPI (N=17) and very high risk group (N=9) according to the CLL-IPI scoring system was 20.1, 17.6, 7.1 and 5.8 months, respectively. Multivariate analysis indicated that del 17p (p<0.008) was independent prognostic factors of TFS.

Conclusions: CLL-IPI is a powerful risk stratification tool for CLL patients and this system has also provided treatment recommendations for different patient risk subgroups.



CLL-IPI, Risk stratification, Survival

Full Text:



Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat. 2009;12(4-5):103-13.

Haselager MV, Kater AP, Eldering E. Proliferative signals in chronic lymphocytic leukemia; what are we missing? Front Oncol. 2020;10:592205.

Dong Y, Shi O, Zeng Q, Xiaoqin L, Wei W, Yong L. et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9:14.

Zengin N, Kars A, Kansu E, Özdemir O, Barişta İ, Güllü İ, et al. Comparison of Rai and Binet classifications in chronic lymphocytic leukemia. Hematology. 1997;2(2):125-9.

Crombie J, Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017;92(12):1393-7.

Rozovski U, Keating MJ, Estrov Z. Why is the immunoglobulin heavy chain gene mutation status a prognostic indicator in chronic lymphocytic leukemia? Acta Haematol. 2018;140(1):51-4.

International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-90.

Hallek M, Cheson B, Catovsky D, Caligaris‐Cappio F, Dighiero G, Döhner H, et al. IWCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-60 .

Wierda WG, O’Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679-85.

Qin SC, Xia Y, Miao Y, Zhu HY, Wu JZ, Fan L, et al. MYD88 mutations predict unfavorable prognosis in chronic lymphocytic leukemia patients with mutated IGHV gene. Blood Cancer J. 2017;7(12):651.

Mauro FR, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, et al. Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Cancers (Basel). 2021;13(13):3240.

Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J, et al. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019;60(6):1438-46.